Meme coins are heating up this September, and Shiba Inu is once again drawing attention with its steady performance.Meme coins are heating up this September, and Shiba Inu is once again drawing attention with its steady performance.

Shiba Inu Latest News; Which Is The Best Crypto To Buy Now For Maximum Gains In September

SPONSORED POST*

Meme coins are heating up this September, and Shiba Inu is once again drawing attention with its steady performance. Still, many traders argue the real opportunity may lie elsewhere. With its presale gaining traction, LBRETT is emerging as the contender that could outshine SHIB as the best crypto to buy now. Here’s why it’s worth the excitement: 

Is This About To Be A September To Remember For Layer Brett (LBRETT)?

Most investors scroll past meme coins expecting nothing more than a quick pump-and-dump, yet Layer Brett is forcing even skeptics to pause and reconsider. Unlike rivals that lean on hype or social energy, this project is starting genuine conversations about utility. This twist is exactly why many are calling it the best crypto to buy now. Instead of banking on jokes, Layer Brett is rolling out real features, including NFT integration, gamified minting, and cross-chain interoperability.

As expected, these features give it a level of depth most meme tokens can’t match. Built as an Ethereum Layer 2 solution, speed and efficiency are baked into its design, putting clear distance between it and projects that burned out too early. In practice, transactions confirm with near-instant finality, while gas fees are so small they are almost invisible.

This efficiency puts Layer Brett in the same conversation as Layer 2 heavyweights like Arbitrum, and zkSync, yet its origins couldn’t be more different. But the narrative isn’t solely about performance metrics; Layer Brett didn’t emerge from corporate boardrooms or polished fundraising tours; it was born from a grassroots community determined to preserve true ownership.

Moreover, this independence is evident in its staking system. Holders can stake their LBRETT tokens directly with ETH, USDT, or BNB, and enjoy more than 700% APY without the need for intermediaries or KYC data. Everything stays in their control, which is exactly what the community wanted. For many investors, the presale represents the most critical stage. Early access not only allows entry at the ground floor, but it also comes with structured incentives designed to increase value long before the token makes its public debut.

SHIB Could Reignite Previous Price Rally Soon

If there’s one thing DeFi traders like to do, it’s to bet on comebacks. Right now, many eyes are back on SHIB as it edges higher after weeks of quiet consolidation. The token recently climbed to around $0.000014, and while the move was modest, it reminded investors that Shiba Inu still has room to surprise.

The general market upswing helped push SHIB off the floor, yet the real story is that the community remains as loyal as ever. This unwavering support continues to breathe life into SHIB even when fundamentals look thin. Analysts are divided because while some believe Shiba Inu has a chance to retest previous highs, others warn that without stronger use cases, the rally could lose steam.

Still, SHIB has never played by the usual rules, and its history proves that sentiment can move price just as much as utility. With optimism returning across crypto, the possibility of another strong SHIB surge feels less like a fantasy and more like a question of timing.

Conclusion 

SHIB and LBRETT are poised for impressive growth this September. LBRETT, in particular, is gaining significant interest, having raised over $3.7 million in its presale in record time. Currently priced at $0.0058, early backers are positioning themselves for potential 20x–50x returns. 

Can You Afford To Miss LBRETT’s Climb To Crypto Stardom? Secure Your LBRETT Tokens Today!


Presale: Layer Brett | Fast & Rewarding Layer 2 Blockchain

Telegram: Telegram: View @layerbrett

X: (1) Layer Brett (@LayerBrett) / X

*This article was paid for. Cryptonomist did not write the article or test the platform.

Market Opportunity
GAINS Logo
GAINS Price(GAINS)
$0.00764
$0.00764$0.00764
-0.39%
USD
GAINS (GAINS) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26